Sujata Patil, PhD

Assistant Attending Biostatistician
Office Phone:
646-735-8182
Office Fax:
646-735-0010
Education:
University of Michigan

Current Research Interests

Dr. Patil’s biostatistical research interests are in longitudinal data analysis, clinical trial design, the analysis of incomplete data, multiple imputation, measurement error models, and Bayesian methods. Other research interests include the analysis of questionnaire data obtained by complex sampling designs. Dr. Patil uses these methods in her clinical collaborations with oncologists and surgeons in the Genitourinary, Breast, and Colorectal Surgery Services. In ongoing work, Dr. Patil is developing methodology that can be used to investigate the relationship between two or more longitudinal biomarkers as predictors of disease outcome. In recent work, she has examined stage migration in metastatic renal cell carcinoma over the last four decades. Dr. Patil serves as a regular lecturer for the Department of Surgery Clinical Research Methods lecture series.

Publications by Sujata Patil

Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Motzer RJ. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2011 Feb;22(2):295-300. Epub 2010 Jul 25. [PubMed Abstract]

Patil S, Ishill N, Deluca J, Motzer RJ. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. Cancer. 2010 Jan 15;116(2):347-54. [PubMed Abstract]

Bosl GJB, Patil SM.  Carboplatin in clinical stage I seminoma: too much and too little at the same time.  J Clin Oncol. 2011 Jan 31. [PubMed Abstract]  

Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ.  Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib versus interferon-alfa.  British Journal of Cancer. [in press]

Patil SM, Shope JT, Raghunathan TE, Bingham CR. The role of personality characteristics in young adult driving. Traffic Inj Prev. 2006 Dec;7(4):328-34. [PubMed Abstract]

Full List of Publications
  1. Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ.  Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib versus interferon-alfa.  British Journal of Cancer. [in press]
  2. Morris P, Murphy C, Mallam D, Accordino M, Patil  S, Howard J, Omur A, Beal  K, Seidman AD, Hudis CA, Fornier M. Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer.  The Breast Journal. [in press]
  3. Murphy CG, Mallam D, Stein S, Patil S, Howard J, Sklarin N, Hudis CA, Gemignani ML, Seidman AD. Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer. Cancer. 2011 Nov 15. doi: 10.1002/cncr.26654. Epub ahead of print. [PubMed Abstract]
  4. McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer. 2011 Jun 16. doi:10.1002/cncr.26171. Epub ahead of print. [PubMed Abstract]
  5. Gucalp A, Sparano J, Caravelli J, Santamauro, Patil S, Abbruzzi A, Pelligrino C, Bromberg J, Dang C, Theodoulou M, Massague J, Norton L, Hudis CA, Traina TA. Phase II trial of Saracatinib (AZD0530), an oral src-inhibitor for the treatment of Patients with Hormone Receptor Negative Metastatic Breast Cancer.  Clin Breast Cancer. 2011 Oct;11(5):306-11. Epub 2011 May 3.
  6. Molina AM, Tickoo SK, Ishill N, Trinos MJ, Schwartz LH, Patil S, Feldman DR, Reuter VE, Russo P, Motzer RJ. Sarcomatoid-variant Renal Cell Carcinoma: Treatment Outcome and Survival in Advanced Disease. Am J Clin Oncol. 2011 Oct;34(5):454-9. [PubMed Abstract]
  7. Kalinsky K, Heguy A, Bhanot U, Patil S, Moynahan ME. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.  Breast Cancer Res Treat. 2011 Sep;129(2):635-43. doi: 10.1007/s10549-011-1601-4. Epub 2011 May 27. [PubMed Abstract]
  8. Kiess AP, McArthur HL, Mahoney K, Patil S, Morris PG, Ho A, Hudis CA, McCormick B. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. Cancer. 2011 Sep 1. doi: 10.1002/cncr.26484. Epub ahead of print. [PubMed Abstract]
  9. Blinder VS, Patil S, Thind A, Diamant A, Hudis C, Basch EM, Maly R.  Return to Work in Low-Income Latina and Non-Latina White Breast Cancer Survivors: A Three-Year Longitudinal Study.  Cancer. 2011 Aug 25. doi: 10.1002/cncr.26478. Epub ahead of print. [PubMed Abstract].
  10. Gajria D, Gonzalez J, Feigin K, Patil S, Chen C, Theodoulou M, Drullinsky P, D'Andrea G, Lake D, Norton L, Hudis CA, Traina TA. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2011 Sep 4. Epub ahead of print. [PubMed Abstract]
  11. Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, Fischer PM, Trinos MJ, Patil SM, Motzer RJ.  Phase I trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma Cancer. 2011 Sep 6. doi: 10.1002/cncr.26429. Epub ahead of print.
  12. Weber WP, Barry M, Stempel MM, Junqueira MJ, Eaton AA, Patil SM, Morrow M, Cody HS 3rd. A 10-Year Trend Analysis of Sentinel Lymph Node Frozen Section and Completion Axillary Dissection for Breast Cancer: Are These Procedures Becoming Obsolete? Ann Surg Oncol. 2011 Jun 7. Epub ahead of print. [PubMed Abstract]
  13. Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, Hansen NA, Kauff ND, Kurtz RC, Kelsen DP, Offit K, Robson ME. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer. 2011 May 19. doi: 10.1002/cncr.26191. Epub ahead of print. [PubMed Abstract]
  14. Feldman DR, Patil S, Trinos MJ, Carousso M, Ginsberg MS, Sheinfeld J, Bajorin DF, Bosl GJ, Motzer RJ. Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design. Cancer. 2011 Jul 26. doi: 10.1002/cncr.26375. Epub ahead of print. [PubMed Abstract]
  15. S. Modi, A. Stopeck, H. Linden, D. Solit, S. Chandarlapaty, N. Rosen, G. D’Andrea, M. Dickler, M. E. Moynahan, S. Sugarman, W. Ma, S. Patil, L. Norton, A. L. Hannah, C. Hudis. HSP90 Inhibition is Effective in Breast Cancer: A Phase 2 Trial of Tanespimycin (17AAG) plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Clin Cancer Res. 2011 May 10. Epub ahead of print. [PubMed Abstract]
  16. Neuman HB, Patil S, Fuzesi S, Wong WD, Weiser MR, Guillem JG, Paty PB, Nash GM, Temple LK. Impact of a Temporary Stoma on the Quality of Life of Rectal Cancer Patients Undergoing Treatment. Ann Surg Oncol. 2011 May;18(5):1397-403. Epub 2010 Dec 3.
  17. King TA, Sakr R, Patil S, Gurevich I, Stempel M, Sampson M, Morrow M.  Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.J Clin Oncol. 2011 Apr 4. Epub ahead of print.
  18. Brogi E, Murphy CG,  Johnson ML, Conlin A, Hsu M,  Patil S, Akram M,  NehhozinaT, Jhaveri KL, Hudis CA, Seidman AD.  Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays.  Annals of Oncology, Advance Access published March 21, 2011.
  19. Gajria D, Feigin K, Tan LK, Patil S, Geneus S, Theodoulou M, Norton L, Hudis CA, Traina TA. Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer.  2011 Mar 8. doi: 10.1002/cncr.25992. Epub ahead of print. [PubMed Abstract]
  20. Morris PG, Chen C, Steingart RM, Fleisher M, Lin NU, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler MN, McArthur HL, Winer EP, Norton L, Hudis C, Dang CT. Troponin I and C-Reactive Protein are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib. Clin Cancer Res. 2011 Mar 3. Epub ahead of print. [PubMed Abstract]
  21. Bosl GJB, Patil SM.  Carboplatin in clinical stage I seminoma: too much and too little at the same time.  J Clin Oncol. 2011 Jan 31. [PubMed Abstract]
  22. Bosl GJ, Patil S.  Reply to S. Stenning et al and J. Lipshitz.  J Clin Oncol Nov 1, 2011:4211-4212.
  23. King TA, Gurevich I, Sakr T, Patil S, Stempel M, Morrow M.  Occult Malignancy in patients undergoing contralateral prophylactic mastectomy.  Ann Surg. 2011 Mar 2. Epub ahead of print. [PubMed Abstract]
  24. McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser MM, Paulson M, Traina TA, Patil S, Zhou Q, Steingart RM, Dang CT, Morrow M, Cordeiro P, Fornier MN, Park JW, Seidman AD, Lake D, Gilewski TA, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson ME, Moynahan ME, Sugarman S, Sealey J, Laragh JH, Merali C, Norton L, Hudis C, Dicker MN. A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel in Early-Stage Breast Cancer. Clin Cancer Res. 2011 Feb. 24. Epub ahead of print. [PubMed Abstract]
  25. Marti JL, Dauer LT, Stempel M, Patil S, Kaplan JB, Montgomery LL. Cumulative imaging radiation exposure following breast-conservation therapy. Ann Surg Oncol. 2011 Jan;18(1):104-8. [PubMed Abstract]
  26. Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Motzer RJ. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2011 Feb;22(2):295-300. Epub 2010 Jul 25. [PubMed Abstract]
  27. Van Zee KJ, Rudloff U, Brogi E, Patil S.  Reply to C. Manzouni et al.  J Clin Oncol. Jan 10, 2011:e45-e46.
  28. Drullinsky P, Sugarman SM, Fornier MN, D'Andrea G, Gilewski T, Lake D, Traina T,  Wasserheit-Lieblich C, Sklarin N, Atieh-Graham D, Mills N, Troso-Sandoval T, Seidman AD, Yuan J, Patel H, Patil S, Norton L, Hudis C. Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. Clin Breast Cancer. 2010 Dec 1;10(6):440-4. [PubMed Abstract]
  29. Arora N, King TA, Jacks LM, Stempel MM, Patil S, Morris E, Morrow M. Impact of breast density on the presenting features of malignancy. Ann Surg Oncol. 2010 Oct;17(Suppl 3):211-8. Epub 2010 Sep 19. [PubMed Abstract]
  30. Pugliese M, Stempel M, Patil S, Hsu M, Ho A, Traina T, Morrow M, Cody H 3rd, Gemignani ML. The clinical impact and outcomes of immunohistochemistry-only metastasis in breast cancer. Am J Surg. 2010 Sep;200(3):368-73. [PubMed Abstract]
  31. Molina AM, Feldman DR, Ginsberg MS, Kroog G, Tickoo SK, Jia X, Georges M, Patil S, Baum MS, Reuter VE, Motzer RJ. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs. 2010 Aug 14. Epub ahead of print. [PubMed Abstract]
  32. Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, Van Zee KJ. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010 Aug 10;28(23):3762-9. Epub 2010 Jul 12. [PubMed Abstract]

  33. Karam AK, Hsu M, Patil S, Stempel M, Traina TA, Ho AY, Cody HS, Morrow M, Gemignani ML. Determinants of outcome in elderly patients with positive sentinel lymph nodes. Am J Surg. 2010 Jul 7. Epub ahead of print. [PubMed Abstract]
  34. Kumar S, Bramlage M, Jacks LM, Goldberg JI, Patil SM, Giri DD, Van Zee KJ.  Minimal disease in the sentinel lymph node: how to best measure sentinel node micrometastases to predict risk of additional non-sentinel lymph node disease. Ann Surg Oncol. 2010 Nov;17(11):2909-19. Epub 2010 Jun 9. [PubMed Abstract]

  35. Morris PG, Lynch C, Feeney JN, Patil S, Howard J, Larson SM, Dickler M, Hudis CA, Jochelson M, McArthur HL. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol. 2010 Jul 1;28(19):3154-9. Epub 2010 Jun 1. [PubMed Abstract]
  36. Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, Norton L, Winer E, Hudis C. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol. 2010 Jun 20;28(18):2982-8. Epub 2010 May 17. Erratum in: J Clin Oncol. 2010 Aug 1;28(22):3670. [PubMed Abstract]
  37. Wright JL, Patil SM, Temple LK, Minsky BD, Saltz LB, Goodman KA. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1064-72. Epub 2010 Mar 29.  [PubMed Abstract]
  38. Rudloff U, Brogi E, Reiner AS, Goldberg JI, Brockway JP, Wynveen CA, McCormick B, Patil S, Van Zee KJ. The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy. Ann Surg. 2010 Apr;251(4):583-91. [PubMed Abstract]
  39. Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, Patil S, Bains M, Reich LM, Bosl GJ, Motzer RJ. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis.  J Clin Oncol. 2010 Apr 1;28(10):1706-13. Epub 2010 Mar 1. Erratum in: J Clin Oncol. 2010 Dec 1;28(34):5126. [PubMed Abstract]
  40. Port ER, Patil S, Stempel M, Morrow M, Cody HS 3rd. Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly  related to patient age and tumor size: a new source of bias in morbidity assessment? Cancer. 2010 Apr 15;116(8):1987-91. [PubMed Abstract]
  41. Morris PG, Poznak CV, Modi S, Mak AF, Patil S, Larson S, Hudis CA, Divgi C, Grewal RK. Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results. Clin Breast Cancer. 2010 Feb;10(1):33-9. [PubMed Abstract]
  42. Pugliese MS, Karam AK, Hsu M, Stempel MM, Patil SM, Ho AY, Traina TA, Van Zee KJ, Cody HS 3rd, Morrow M, Gemignani ML. Predictors of completion axillary lymph  node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer. Ann Surg Oncol. 2010 Apr;17(4):1063-8. Epub 2009 Dec 22. [PubMed Abstract]
  43. Patil S, Ishill N, Deluca J, Motzer RJ. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. Cancer. 2010 Jan 15;116(2):347-54. [PubMed Abstract]

  44. Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, Park JW, Geneus S, Paulson M, Grothusen J, Seidman AD, Fornier M, Lake D, Dang C, Robson M, Theodoulou M, Flombaum CD, Norton L, Hudis CA, Dickler MN. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol. 2010 Feb 1;28(4):628-33. Epub 2009 Oct 19. [PubMed Abstract]
  45. Korkola JE, Houldsworth J, Feldman DR, Olshen AB, Qin LX, Patil S, Reuter VE, Bosl GJ, Chaganti RS. Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. J Clin Oncol. 2009 Nov 1;27(31):5240-7. Epub 2009 Sep 21. [PubMed Abstract]
  46. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009 Aug 15;15(16):5049-59. Epub 2009 Aug 11. [PubMed Abstract]
  47. Hurria A, Li D, Hansen K, Patil S, Gupta R, Nelson C, Lichtman SM, Tew WP, Hamlin P, Zuckerman E, Gardes J, Limaye S, Lachs M, Kelly E. Distress in older patients with cancer. J Clin Oncol. 2009 Sep 10;27(26):4346-51. Epub 2009 Aug 3. [PubMed Abstract]
  48. Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, Morrow M. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol. 2009 Oct;16(10):2705-10. Epub 2009 Jul 11. [PubMed Abstract]
  49. Feldman DR, Turkula S, Ginsberg MS, Ishill N, Patil S, Carousso M, Bosl GJ, Motzer RJ. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2010 Aug;28(4):523-8. Epub 2009 Jun 23. [PubMed Abstract]
  50. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong WD, Paty PB. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009 Jul 10;27(20):3379-84. Epub 2009 Jun 1. [PubMed Abstract]
  51. Karam AK, Hsu M, Patil S, Stempel M, Traina TA, Ho AY, Cody HS, Port ER, Morrow M, Gemignani ML. Predictors of completion axillary lymph node dissection in patients with positive sentinel lymph nodes. Ann Surg Oncol. 2009 Jul;16(7):1952-8. Epub 2009 Apr 18. [PubMed Abstract]
  52. Temple L, Fuzesi S, Patil S. The importance of determining quality of life in clinical trials. Surgery. 2009 Jun;145(6):622-6. Epub 2009 Apr 16. [PubMed Abstract]
  53. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, Fischer  P, Ronnen E, Ishill N, Patil S, Motzer RJ. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J  Clin Oncol. 2009 Mar  0;27(9):1432-9. Epub 2009 Feb 17. [PubMed Abstract]
  54. Rudloff U, Brogi E, Brockway JP, Goldberg JI, Cranor M, Wynveen CA, Nehhozina T, Reiner AS, Patil S, Van Zee KJ. Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2009 Mar 15;115(6):1203-14.  Erratum in: Cancer. 2010 Apr 15;116(8):2064. [PubMed Abstract]
  55. Chung A, Yu J, Stempel M, Patil S, Cody H, Montgomery L. Is the “10% rule” equally valid for all subsets of sentinel-node-positive breast cancer patients? Ann Surg Oncol. 2008  Oct;15(10):2728-33. Epub 2008 Aug 8. [PubMed Abstract]
  56. Zauderer M, Patil S, Hurria A. Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. Breast Cancer Res Treat. 2009 Sep;117(1):205-10. Epub 2008 Jul 13. [PubMed Abstract]
  57. Feldman DR, Kondagunta GV, Schwartz L, Patil S, Ishill N, DeLuca J, Russo P,  Motzer RJ. Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2008 Mar;6(1):25-30. [PubMed Abstract]
  58. Jathavedam A, Feldman DR, Ishill N, Turkula S, Patil S, Bosl GJ, Motzer RJ, Weinstock DM. Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. Biol Blood Marrow Transplant. 2008 May;14(5):595-600. [PubMed Abstract]
  59. Traina TA, Theodoulou M, Feigin K, Patil S, Tan KL, Edwards C, Dugan U, Norton L, Hudis C. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol. 2008 Apr 10;26(11):1797-802. [PubMed Abstract]
  60. Flynn LW, Park J, Patil SM, Cody HS 3rd, Port ER. Sentinel lymph node biopsy  is successful and accurate in male breast carcinoma. J Am Coll Surg. 2008 Apr;206(4):616-21. Epub 2008 Feb 21. [PubMed Abstract]
  61. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum. 2008 Feb;51(2):147-53. Epub 2008 Jan 8. Erratum in: Dis Colon Rectum. 2008 May;51(5):620. [PubMed Abstract]

  62. McLaughlin SA, Ochoa-Frongia LM, Patil SM, Cody HS 3rd, Sclafani LM. Influence of frozen-section analysis of sentinel lymph node and lumpectomy margin status on reoperation rates in patients undergoing breast-conservation therapy. J Am Coll Surg. 2008 Jan;206(1):76-82. Epub 2007 Oct 18. [PubMed Abstract]
  63. Fornier M, Rathkopf D, Shah M, Patil SM, O’Reilly E, Tse A, Hudis C, Kelsen DP, Schwartz.  Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors, CCR-07-1218 Version 2.  Clinical Cancer Research 13(19): 5841-5846, 2007.
  64. Dang C, Patil SM.  Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.  Letter in response to Gennari et al Journal of Clinical Oncology 24: 3912-3918, 2006.  Breast Diseases:  A Yearbook Quarterly 18(3): 305, 2007.
  65. Chelliah A, Heydon KH, Zaoutis TE, Rettig SL, Dominguez TE, Lin R, Patil S, Feudtner C, St John KH, Bell LM, Coffin SE. Observational trial of antibiotic-coated central venous catheters in critically ill pediatric patients.  Pediatr Infect Dis J. 2007 Sep;26(9):816-20. [PubMed Abstract]
  66. Hurria A, Lichtman SM, Gardes J, Li D, Limaye S, Patil S, Zuckerman E, Tew W, Hamlin P, Abou-Alfa GK, Lachs M, Kelly E. Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. J Am Geriatr Soc. 2007 Oct;55(10):1604-8. Epub 2007 Aug 14. [PubMed Abstract]
  67. Barrio AV, Clark BD, Goldberg JI, Hoque LW, Bernik SF, Flynn LW, Susnik B, Giri D, Polo K, Patil S, Van Zee KJ. Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol. 2007 Oct;14(10):2961-70. Epub 2007 Jun 12. [PubMed Abstract]
  68. Feldman DR, Kondagunta GV, Ginsberg MS, Ishill N, Patil S, Cestaro J, Obbens  E, Sheinfeld J, Bosl GJ, Motzer RJ. Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Invest New Drugs. 2007 Oct;25(5):487-90. Epub 2007 May 23. [PubMed Abstract]
  69. Patil SM, Shope JT, Raghunathan TE, Bingham CR. The role of personality characteristics in young adult driving. Traffic Inj Prev. 2006 Dec;7(4):328-34. [PubMed Abstract]

  70. Davis JA, McBride MG, Chrisant MR, Patil SM, Hanna BD, Paridon SM. Longitudinal assessment of cardiovascular exercise performance after pediatric heart transplantation. J Heart Lung Transplant. 2006 Jun;25(6):626-33. Epub 2006  May 2. [PubMed Abstract]
  71. Steenhoff AP, Shah SS, Ratner AJ, Patil SM, McGowan KL. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin Infect Dis. 2006 Apr 1;42(7):907-14. Epub 2006 Feb 27. [PubMed Abstract]
  72. Steenhoff AP, Shah SS, Ratner AJ, Patil SM, McGowan KL. Reply to Robertson et al. Clinical Infectious Diseases, 43:544-545, 2006.
  73. Gross SR, Jacoby K, Matheson DJ, Montgomery N, Patil SM. Exonerations in the United States 1989 through 2003, Journal of Criminal Law and Criminology. 95(2) 2005.
  74. Shope JT, Raghunathan TE, Patil SM. Examining trajectories of adolescent risk factors as predictors of subsequent high-risk driving behavior. J Adolesc Health. 2003 Mar;32(3):214-24. [PubMed Abstract]
  75. Shope JT, Waller PF, Raghunathan TE, Patil S. Adolescent antecedents of high-risk driving behavior in young adulthood: substance use and parental influences. Accident Analysis and Prevention. 33: 649­-658, 2001
  76. Anderson DR, Patil SM, Kamina A, Penson DF, Peduzzi P, Concato J. Validation and modification of a staging system for evaluating prognosis in prostate cancer. Connecticut Medicine. 64(8):459-464, 2000.